Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Picrotoxin

    go.drugbank.com/drugs/DB00466
    Experimental

    Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. [PubChem] … A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the gamma-aminobutyric acid-activated chloride ionophore.

    Categories: Compounds used in a research, industrial, or household setting, GABA-A Receptor Antagonists
  2. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific … Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

    Synonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
  3. Drug

    Calcium threonate

    go.drugbank.com/drugs/DB11168
    ApprovedWithdrawn

    L-threonate is an active metabolite of vitamin C that mediates a stimulatory action on vitamin C uptake [A27266]. … It is found in dietary supplements as a source of L-threonate used in the treatment of calcium deficiency and prevention of osteoporosis.

    Synonyms: Calcium L-threonate
  4. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes. … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.

    Products: OLO-A-DAY, Pataday Twice A Day Relief
  5. Drug

    Ephedrine

    go.drugbank.com/drugs/DB01364
    ApprovedInvestigational

    Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]

    Mixtures: COPHADYL-E COUGH LINCTUS, ColdaeWon Cold ASynonyms: L-Ephedrine, L(−)-ephedrine
  6. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC

  7. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Piperazine is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms.

    Products: PIPERAZINA AL 10%, PIPERAZINA AL 20%
  8. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.

  9. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    It is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years.

  10. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was